NCT06976437View on ClinicalTrials.gov

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

May 20, 2027

Study Completion Date

December 30, 2027

Conditions
B Cell LymphomaMultiple Myeloma
Interventions
DRUG

RN1101 injection

RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.

Trial Locations (1)

212001

RECRUITING

Affiliated Hospital of Jiangsu University, Zhenjiang

Sponsors

Collaborators (1)

Allorunning Therapeutics
All Listed Sponsors
collaborator

Rui Therapeutics Co., Ltd

INDUSTRY

collaborator

Allorunning Therapeutics

INDUSTRY

lead

YANRU WANG

OTHER

NCT06976437 - A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | Biotech Hunter | Biotech Hunter